Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fluoro-alkyl-cyclopeptide derivatives having anti-integrin activity

A compound and drug technology, applied in the field of fluoro-alkyl-cyclic peptide derivatives, can solve problems affecting proteolytic stability and solubility

Inactive Publication Date: 2005-08-31
SIGMA TAU IND FARMACEUTICHE RIUNITE SPA
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Moreover, the substitution of fluorine for hydrogen may affect the proteolytic stability and solubility of peptides containing it (Koksch, B., J. Pept. Sci., 1997, 3, 157-67)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fluoro-alkyl-cyclopeptide derivatives having anti-integrin activity
  • Fluoro-alkyl-cyclopeptide derivatives having anti-integrin activity
  • Fluoro-alkyl-cyclopeptide derivatives having anti-integrin activity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0079] C(Arg-Glv-Asp-D-Phe-(R or S)-Tfm-Phe) (ST1930 / ST1931)

[0080] Preparation of Pht-D-Phe-Br (Dal Pozzo, A., Bergonzi, R. and Ni, M.H., Tetrahedron Lett., 2001, 42, 3925-7).

[0081] 1.4 g (4.75 mmol) Pht-D-Phe-OH were dissolved in 19 ml of a 0.5 M solution of bromoenamine in DCM under argon. After 10 minutes, the solution is ready to use.

[0082] Add 248mg (0.950mmol) of H-α-Tfm-Phe-OEt and collidine (1 equivalent) to 12.5ml of bromide solution (prepared as above) cooled to 0°C, stir the mixture at room temperature (a.t.), after 10 minutes Another 6.5 ml portion of the bromide solution and 1 equivalent of collidine were added. After 2 h the mixture was dried with 15 ml of 5% NaHCO 3 and 15 ml EtOAc, and stirred for 30 minutes. The solvent was washed with water, 1N HCl and water, then evaporated and the residue was purified on a flash column using 8:2 hexane-EtOAc as solvent.

[0083] 4.3ml of 1M BBr 3 The DCM solution of 460 mg of dipeptide Pht-D-Phe-α-Tfm-Phe-O...

Embodiment 2

[0110] c(Arg-Gly-Asp-D-Phe-(R,S)-Dfm-Phe) (ST1932)

[0111] Proceed as described in Example 1 starting from H-(R,S)-Dfm-Phe-OEt. A mixture of the two diastereoisomers was obtained which had not yet been resolved.

[0112] 1 H-NMR (CD 3 OD): δ8.00-7.05 (d, NH), 7.35-7.15 (m, aromatics), 6.42-5.6 (t, CHF 2 ), 4.74-4.32 (m, α-CH), 4.32-3.96 (2 dd, CH 2 -Gly), 3.68-2.50(m), 1.75-1.45(m, CH 2 -CH 2 -Arg).

[0113] 19 F-NMR (CD 3 OD): δ -54.4 to -55.5.

[0114] MS (M+H + ): 673.14.

Embodiment 3

[0116] c(Arg-Gly-(R or S)-Tfm-Asp-D-Phe-Val)(ST2189 / 2190)

[0117] H-(R,S)-Tfm-Allgly-Oet was condensed with Pth-Gly-Br and then worked up as described in Example 1. With preparative HPLC, containing 22% CH 3 CN in water + 0.1% TFA resolved and purified the mixture of two diastereoisomers.

[0118] Diastereomer I (Rt 20.76)

[0119] 1 H-NMR (DMSOD 6 +D 2 O): δ7.30-7.12, 4.70, 4.26, 4.10, 3.86, 3.60-2.70, 1.72, 1.52-1.12, 0.65.

[0120] MS (M+H + ): 643.2.

[0121] Diastereomer II (Rt 25.44)

[0122] 1 H-NMR (DMSOD 6 +D 2 O): δ7.30-6.96, 4.50, 4.15, 4.10-2.75, 1.90, 1.62, 1.43-1.20, 0.82.

[0123] MS (M+H + ): 643.2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Compounds of formula (I) cyclo [NX1-R1-CO-NX2-R2-CO-NX3-R3-CO-NX4-CO-NX5-R5-CO], wherein at least one x-fluoroalkylated amino acid is present, are inhibitors of integrins, particularly those belonging to the alphavbeta3 and alphavbeta5 family, and thus are useful as medicaments, particularly for the treatment of the underlying diseases responsible for abnormal angiogenesis, such as retinopathy, acute kidney failure, osteoporosis and metastases. The compounds described herein are also useful as diagnostic agents, when appropriately labelled, especially for the detection and location of small tumour masses and arterial occlusion events.

Description

[0001] The invention described here relates to fluoro-alkyl-cyclic peptide derivatives having anti-integrin activity, in particular to cyclic peptide compounds containing a fluoro-alkyl group at the nitrogen and / or C-alpha position of the peptide bond, as follows Shown in the formula (I). The invention described here also relates to processes for the preparation of said compounds, their use as medicaments, especially as integrin receptor inhibitors, as anti-angiogenic and anti-metastatic agents, and to pharmaceutical compositions comprising them. Background of the invention [0002] Integrins are a class of receptors involved in the phenomenon of cell adhesion. They are glycoproteins composed of two subunits, D and β, that combine to form distinct families. For a more detailed description see Kessler, H., et al., Angew. Chem. Int. Ed. Engl., 1997, 36, 1374-89. [0003] All integrins have a "universal cellular recognition site" that recognizes the common peptide sequence Arg-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00C07K7/54C07K7/64
CPCC07K7/54A61K38/00C07K7/64A61P13/12A61P19/10A61P27/02A61P35/00A61P35/04A61P43/00A61P9/10A61P9/14A61K38/12G01N33/68
Inventor A·达尔波佐G·吉安尼尼C·皮萨诺
Owner SIGMA TAU IND FARMACEUTICHE RIUNITE SPA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com